Clinical Trial: A Phase 1/2 Study of KHN922 for Injection

U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07514975) titled 'A Phase 1/2 Study of KHN922 for Injection' on March 23.

Brief Summary: A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors Cancer

Intervention: DRUG: KHN922 for injection

KHN922 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting HER3 antigens，intravenous (IV) administration every three weeks (D1) .

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chengdu Kanghong Biotech Co., Ltd.

Published...